Combining Topical Imiquimod With Local Radiotherapy for Treatment of Mycosis Fungoides
Recruiting
Early Phase 1
Interventional Study
Mycosis Fungoides
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
At a Glance
- Age
- 18 – 90
- Sex
- Any
- Trial phase
- Early Phase 1
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 25 (estimated)
- Sponsor
- Northwestern University · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
Mycosis fungoides (MF) is the most common subtype of cutaneous T cell lymphoma (MF) and presents as cutaneous patches, plaques, and tumors. Radiation therapy (RT) is a frequently pursued management option for CTCL, especially in patients with more advanced skin disease. Imiquimod stimulates a Th1 lymphocyte response with increased IL-2 and IFN-α, but also induces IFN-α, TNF-α, IL-1α, IL-6, and IL-…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Patients must have confirmed stage IA-IIB mycosis fungoides.
* Patients must be 18-90 years of age.
* Patients must have failed at least one standard therapy for MF.
* Patients must have active, but stable disease for \>6 months.
* Patients must have 4 or more discrete MF lesi…
Contacts